Biomedical device company Biotronik said the U.S. Food and Drug Administration (FDA) has cleared its Edora HF-T QP, an MR-conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI AutoDetect technology.
Edora HF-T QP has a volume of 15 cubic centimeters and longevity of nearly 10 years, reducing the frequency of device replacements for heart failure patients. It features MRI AutoDetect, closed loop stimulation, and the company's home monitoring technology with automatic daily transmission verification. The Biotronik home monitoring system provides a summary of nine long-term heart failure statistics, helping physicians continuously monitor and evaluate patients' heart failure status.
